Rheumatoid Arthritis Therapy “Healing” Evidence Lacks Precision, FDAer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Evidence of structural damage healing by rheumatoid arthritis agents has been incorrectly interpreted in some cases, FDA Medical Team Leader Siegel says. Radiographic signs of healing are often “statistical noise” or “an imprecision of readings.”
You may also be interested in...
Remicade Sales Aid Makes Misleading Efficacy Claims, FDA Tells J&J
Sales aid improperly suggests the TNF-inhibitor can reverse or heal the disease process in patients with early rheumatoid arthritis, an FDA ad division “untitled” letter states. Agency also cites the promotion for omitting risk information. Centocor says the sales aid has not been used since October.
Remicade Gets First-Line Rheumatoid Arthritis Claim On Data In Early Disease
J&J's infliximab is approved for first-line RA treatment in combination with methotrexate. Approval is based on 54-week ASPIRE trial showing superiority in early RA; study also shows preventative benefit in patients without initial joint damage.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.